Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 8/20 | 1.00 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 1.00 |
| ▸ | BRPF1 | P55201 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8481500 | 0.74 | HTT (0.75) | CREBBPBRD9BRPF1HTTMEN1 | |
| SCHEMBL887130 | 0.72 | CREBBP (0.55) | CREBBPBRD9BRPF1HTTMEN1 | |
| SCHEMBL5328547 | 0.71 | CREBBP (0.55) | CREBBPBRD9BRPF1HTTMEN1 | |
| SCHEMBL8806504 | 0.70 | CCNE2 (0.76) | GSK3B | |
| SCHEMBL3238254 | 0.69 | CREBBP (0.53) | CREBBPBRD9BRPF1HTTGSK3B | |
| SCHEMBL1333179 | 0.69 | HTT (0.54) | CREBBPBRD9BRPF1HTTMEN1 | |
| SCHEMBL887129 | 0.69 | HTT (0.54) | CREBBPBRD9BRPF1HTTMEN1 | |
| SCHEMBL15177773 | 0.69 | HTT (0.55) | CREBBPBRD9BRPF1HTTMEN1 | |
| SCHEMBL16481902 | 0.68 | HTT (0.53) | CREBBPBRD9BRPF1HTTALDH1A1 | |
| SCHEMBL13806317 | 0.67 | POLB (0.54) | CREBBPBRD9BRPF1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CREBBP 132/4885BRD9 2024/4885BRPF1 1138/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CREBBP 132/4885BRD9 2024/4885BRPF1 1138/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | CREBBP 1345/4885BRD9 4029/4885BRPF1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.